X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA JUBILANT LIFE SCIENCES SHASUN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 123.9 19.1 647.5% View Chart
P/BV x 8.5 3.9 217.2% View Chart
Dividend Yield % 0.2 0.5 50.4%  

Financials

 SHASUN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
SHASUN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs94187 50.4%   
Low Rs4665 70.0%   
Sales per share (Unadj.) Rs214.2364.3 58.8%  
Earnings per share (Unadj.) Rs5.36.8 77.9%  
Cash flow per share (Unadj.) Rs15.824.5 64.6%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %1.42.4 60.1%  
Book value per share (Unadj.) Rs53.3164.9 32.3%  
Shares outstanding (eoy) m56.62159.28 35.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 94.4%   
Avg P/E ratio x13.118.4 71.2%  
P/CF ratio (eoy) x4.45.1 85.9%  
Price / Book Value ratio x1.30.8 171.6%  
Dividend payout %18.743.8 42.8%   
Avg Mkt Cap Rs m3,95820,061 19.7%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m2,16411,052 19.6%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m12,12758,034 20.9%  
Other income Rs m229191 120.3%   
Total revenues Rs m12,35658,224 21.2%   
Gross profit Rs m1,0095,786 17.4%  
Depreciation Rs m5942,812 21.1%   
Interest Rs m4153,237 12.8%   
Profit before tax Rs m230-72 -318.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m-73696 -10.4%   
Profit after tax Rs m3021,090 27.7%  
Gross profit margin %8.310.0 83.5%  
Effective tax rate %-31.7-965.9 3.3%   
Net profit margin %2.51.9 132.6%  
BALANCE SHEET DATA
Current assets Rs m6,88429,280 23.5%   
Current liabilities Rs m8,45638,912 21.7%   
Net working cap to sales %-13.0-16.6 78.1%  
Current ratio x0.80.8 108.2%  
Inventory Days Days6284 73.0%  
Debtors Days Days10851 212.2%  
Net fixed assets Rs m4,97055,712 8.9%   
Share capital Rs m113155 73.3%   
"Free" reserves Rs m2,87520,968 13.7%   
Net worth Rs m3,02026,265 11.5%   
Long term debt Rs m1,81717,169 10.6%   
Total assets Rs m13,34788,606 15.1%  
Interest coverage x1.61.0 158.9%   
Debt to equity ratio x0.60.7 92.1%  
Sales to assets ratio x0.90.7 138.7%   
Return on assets %5.44.9 110.0%  
Return on equity %10.04.2 241.0%  
Return on capital %13.311.6 115.2%  
Exports to sales %46.437.8 122.7%   
Imports to sales %14.216.5 86.4%   
Exports (fob) Rs m5,62221,933 25.6%   
Imports (cif) Rs m1,7289,567 18.1%   
Fx inflow Rs m5,84322,004 26.6%   
Fx outflow Rs m2,17311,749 18.5%   
Net fx Rs m3,66910,255 35.8%   
CASH FLOW
From Operations Rs m3988,026 5.0%  
From Investments Rs m-1,635-1,744 93.7%  
From Financial Activity Rs m1,309-4,447 -29.4%  
Net Cashflow Rs m711,834 3.9%  

Share Holding

Indian Promoters % 39.2 45.6 86.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 3.6 8.7 41.4%  
FIIs % 17.6 21.2 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 21.1 187.7%  
Shareholders   20,750 23,815 87.1%  
Pledged promoter(s) holding % 12.3 15.9 77.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull End to the Trading Day; Metal & Auto Stocks Fall(Closing)

Indian share markets continued to trade range-bound in the afternoon session amid mixed international markets. At the closing bell, the BSE Sensex closed higher by 27 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS